479 related articles for article (PubMed ID: 23045237)
1. B cells and antibodies in multiple sclerosis pathogenesis and therapy.
Krumbholz M; Derfuss T; Hohlfeld R; Meinl E
Nat Rev Neurol; 2012 Nov; 8(11):613-23. PubMed ID: 23045237
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
[TBL] [Abstract][Full Text] [Related]
3. B cell characterization and reactivity analysis in multiple sclerosis.
Fraussen J; Vrolix K; Martinez-Martinez P; Losen M; De Baets MH; Stinissen P; Somers V
Autoimmun Rev; 2009 Jul; 8(8):654-8. PubMed ID: 19239929
[TBL] [Abstract][Full Text] [Related]
4. The BAFF / APRIL system as therapeutic target in multiple sclerosis.
Magliozzi R; Marastoni D; Calabrese M
Expert Opin Ther Targets; 2020 Nov; 24(11):1135-1145. PubMed ID: 32900236
[TBL] [Abstract][Full Text] [Related]
5. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid.
Owens GP; Bennett JL; Lassmann H; O'Connor KC; Ritchie AM; Shearer A; Lam C; Yu X; Birlea M; DuPree C; Williamson RA; Hafler DA; Burgoon MP; Gilden D
Ann Neurol; 2009 Jun; 65(6):639-49. PubMed ID: 19557869
[TBL] [Abstract][Full Text] [Related]
6. Dual Role of B Cells in Multiple Sclerosis.
Kumar G; Axtell RC
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768658
[TBL] [Abstract][Full Text] [Related]
7. Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system?
Meier UC; Giovannoni G; Tzartos JS; Khan G
Clin Exp Immunol; 2012 Jan; 167(1):1-6. PubMed ID: 22132878
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis - established and novel therapeutic approaches.
Ehling R; Berger T; Reindl M
Cent Nerv Syst Agents Med Chem; 2010 Mar; 10(1):3-15. PubMed ID: 20236038
[TBL] [Abstract][Full Text] [Related]
9. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
[TBL] [Abstract][Full Text] [Related]
10. The role of B cells in multiple sclerosis: Current and future therapies.
Negron A; Robinson RR; Stüve O; Forsthuber TG
Cell Immunol; 2019 May; 339():10-23. PubMed ID: 31130183
[TBL] [Abstract][Full Text] [Related]
11. Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis.
Villar LM; Espiño M; Cavanillas ML; Roldán E; Urcelay E; de la Concha EG; Sádaba MC; Arroyo R; González-Porqué P; Alvarez-Cermeño JC
Clin Immunol; 2010 Oct; 137(1):51-9. PubMed ID: 20621566
[TBL] [Abstract][Full Text] [Related]
12. The role of antibodies in multiple sclerosis.
Weber MS; Hemmer B; Cepok S
Biochim Biophys Acta; 2011 Feb; 1812(2):239-45. PubMed ID: 20600871
[TBL] [Abstract][Full Text] [Related]
13. The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting.
Baert L; Manfroi B; Casez O; Sturm N; Huard B
J Autoimmun; 2018 Dec; 95():179-190. PubMed ID: 30385081
[TBL] [Abstract][Full Text] [Related]
14. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis.
Quan C; Yu H; Qiao J; Xiao B; Zhao G; Wu Z; Li Z; Lu C
Mult Scler; 2013 Mar; 19(3):289-98. PubMed ID: 22864301
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis.
Gharibi T; Ahmadi M; Seyfizadeh N; Jadidi-Niaragh F; Yousefi M
Cell Immunol; 2015 Feb; 293(2):113-21. PubMed ID: 25596473
[TBL] [Abstract][Full Text] [Related]
16. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
He B; Chadburn A; Jou E; Schattner EJ; Knowles DM; Cerutti A
J Immunol; 2004 Mar; 172(5):3268-79. PubMed ID: 14978135
[TBL] [Abstract][Full Text] [Related]
17. Effector and regulatory B cells in Multiple Sclerosis.
Staun-Ram E; Miller A
Clin Immunol; 2017 Nov; 184():11-25. PubMed ID: 28461106
[TBL] [Abstract][Full Text] [Related]
18. Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis.
Baker D; Pryce G; James LK; Schmierer K; Giovannoni G
Eur J Neurol; 2020 Feb; 27(2):221-228. PubMed ID: 31617269
[TBL] [Abstract][Full Text] [Related]
19. A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ray A; Mann MK; Basu S; Dittel BN
J Neuroimmunol; 2011 Jan; 230(1-2):1-9. PubMed ID: 21145597
[TBL] [Abstract][Full Text] [Related]
20. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
Blumenfeld S; Staun-Ram E; Miller A
J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
